Landscape Capital Management L.L.C. Decreases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Landscape Capital Management L.L.C. reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 28.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 266,657 shares of the company’s stock after selling 108,088 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Hims & Hers Health were worth $4,912,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the period. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter worth $111,000. Finally, Amalgamated Bank raised its holdings in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Stock Down 7.4 %

Shares of HIMS stock opened at $21.80 on Thursday. The stock has a market cap of $4.76 billion, a P/E ratio of 49.55 and a beta of 1.06. The business has a fifty day simple moving average of $20.21 and a 200-day simple moving average of $19.09. Hims & Hers Health, Inc. has a fifty-two week low of $7.51 and a fifty-two week high of $30.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.04) earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the sale, the insider now owns 159,796 shares of the company’s stock, valued at $2,341,011.40. The trade was a 1.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Anja Manuel purchased 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at approximately $107,760. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 1,056,183 shares of company stock valued at $21,501,682 in the last three months. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.